CAS 944548-37-2|rafivirumab
Introduction：Basic information about CAS 944548-37-2|rafivirumab, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | rafivirumab | ||
|---|---|---|---|
| CAS Number | 944548-37-2 | Molecular Weight | / |
| Density | / | Boiling Point | / |
| Molecular Formula | / | Melting Point | / |
| MSDS | / | Flash Point | / |
Names
| Name | rafivirumab |
|---|
rafivirumab BiologicalActivity
| Description | Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails[1][2][3]. |
|---|---|
| Related Catalog | Research Areas >>Infection |
| In Vitro | Rafivirumab 显示出对一系列 RABV 分离株的中和作用[2]。 Rafivirumab 与 RABV 糖蛋白的抗原位点 I 结合[3]。 Rafivirumab 完全中和野生型 ERA439 和 N336D R346K，EC50 范围在 3 到 5 pg/mL 之间[3]。 |
| In Vivo | Rafivirumab (3-12 μg/kg，肌肉注射) 与 CR4098 一起提高了感染蝙蝠狂犬病病毒的叙利亚仓鼠的存活率[2]。 Animal Model: Syrian hamsters infected with bat rabies viruses[2]. Dosage: 6, 12, 16, 18 or 24 μg/kg of CL184 (mixture of Rafivirumab and CR4098 in 1:1 protein ratio) Administration: i.m. Result: Increased survival rate. |
| References | [1]. Kramer RA, et al. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol. 2005 Jul;35(7):2131-45. [2]. Franka R, et al. In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants. Trop Med Infect Dis. 2017 Sep 20;2(3):48. [3]. Ejemel M, et al. A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis. Sci Rep. 2022 Jun 7;12(1):9403. |
Chemical & Physical Properties
| No Any Chemical & Physical Properties |
